“Drug Manufacturer’s Risky Practices”
Previously, I have said, “Pharmaceutical companies have egregiously participated in one hundred years of sleazy practices and continue to do so.” According to a 2013 article in the Journal of Law, Medicine and Ethics (JLME), here is the heart of the problem: about 350 people die daily from drug reactions or 128,000 per year. Pharmaceutical companies hide, ignore, or misrepresent evidence about new drugs; distort the medical literature; and misrepresent products to prescribing physicians. There appears to be an epidemic of harmful allowable Food and Drug Administration (FDA) approved drugs, which have scarce benefits to any patients. A 2018 report shows that Nuplazid, a drug for hallucinations and delusions associated with Parkinson’s disease, failed two clinical trials. In a third trial, under a revised standard for measuring its effect, it showed minimal benefit. Overall, more patients died or had serious side effects on Nuplazid than after
receiving no treatment. Also, patients on Uloric, a gout drug, suffered more heart attacks, strokes and heart failure in two out of three trials than did their counterparts on standard or no medication.
